Marshall Wace’s Marker Therapeutics MRKR Stock Holding History

Marshall Wace’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,348	Closed	-$117K	–	3761
2021 Q4	$117K	Sell	12,348 -4,723	-28%	-$62.7K	﹤0.01%	3344
2021 Q3	$289K	Sell	17,071 -15,712	-48%	-$322K	﹤0.01%	2663
2021 Q2	$915K	Buy	+32,783	New	+$863K	﹤0.01%	1861
2020 Q1	–	Sell	-13,979	Closed	-$403K	–	1908
2019 Q4	$403K	Sell	13,979 -2,161	-13%	-$78.6K	﹤0.01%	1219
2019 Q3	$825K	Buy	+16,140	New	+$954K	0.01%	989

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Marshall Wace's MRKR Position: Q1 2022 in Review

Marshall Wace sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 12,348 shares — an estimated $117K sold.

Marshall Wace first reported a position in MRKR in Q3 2019 and held it in 5 quarters. The position peaked at $915K in Q2 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Marshall Wace reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 12,348 Marker Therapeutics shares in Q1 2022, an estimated $117K.
Marshall Wace first reported a position in Marker Therapeutics in Q3 2019 and held it in 5 quarters.
Marshall Wace's Marker Therapeutics position peaked at $915K in Q2 2021.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.